Sangamo Therapeutics Inc (SGMO) - Total Liabilities
Based on the latest financial reports, Sangamo Therapeutics Inc (SGMO) has total liabilities worth $82.40 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SGMO long-term investment intensity to see how much of total assets are deployed in long-term investments.
Sangamo Therapeutics Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how Sangamo Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SGMO current and non-current assets.
Sangamo Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sangamo Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hamilton Global Opportunities PLC
PA:ALHGO
|
France | €5.46 Million |
|
Bowen Acquisition Corp Ordinary Shares
NASDAQ:BOWN
|
USA | $2.61 Million |
|
Systech Bhd
KLSE:0050
|
Malaysia | RM290.19 Million |
|
Perimeter Medical Imaging AI Inc
V:PINK
|
Canada | CA$2.51 Million |
|
Haatz Inc
KQ:066130
|
Korea | ₩45.68 Billion |
|
Quince Therapeutics, Inc.
NASDAQ:QNCX
|
USA | $15.51 Million |
|
Hove AS
CO:HOVE
|
Denmark | Dkr28.14 Million |
|
Moonbae Steel
KO:008420
|
Korea | ₩44.94 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Sangamo Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sangamo Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 13.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sangamo Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sangamo Therapeutics Inc (1996–2024)
The table below shows the annual total liabilities of Sangamo Therapeutics Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $78.86 Million | -4.33% |
| 2023-12-31 | $82.43 Million | -69.19% |
| 2022-12-31 | $267.55 Million | -22.80% |
| 2021-12-31 | $346.58 Million | -21.44% |
| 2020-12-31 | $441.18 Million | +115.45% |
| 2019-12-31 | $204.78 Million | -8.53% |
| 2018-12-31 | $223.88 Million | +126.50% |
| 2017-12-31 | $98.84 Million | +355.57% |
| 2016-12-31 | $21.70 Million | -12.50% |
| 2015-12-31 | $24.80 Million | -32.21% |
| 2014-12-31 | $36.58 Million | +91.23% |
| 2013-12-31 | $19.13 Million | +8.45% |
| 2012-12-31 | $17.64 Million | +144.82% |
| 2011-12-31 | $7.20 Million | +1.58% |
| 2010-12-31 | $7.09 Million | -54.70% |
| 2009-12-31 | $15.66 Million | +25.72% |
| 2008-12-31 | $12.45 Million | +5.74% |
| 2007-12-31 | $11.78 Million | +66.47% |
| 2006-12-31 | $7.08 Million | -36.66% |
| 2005-12-31 | $11.17 Million | +375.68% |
| 2004-12-31 | $2.35 Million | +49.46% |
| 2003-12-31 | $1.57 Million | -20.70% |
| 2002-12-31 | $1.98 Million | -25.75% |
| 2001-12-31 | $2.67 Million | +31.11% |
| 2000-12-31 | $2.04 Million | +56.54% |
| 1999-12-31 | $1.30 Million | +107.01% |
| 1998-12-31 | $628.00K | +28.95% |
| 1997-12-31 | $487.00K | +363.81% |
| 1996-12-31 | $105.00K | -- |
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more